Antibody-drug conjugate
Antibody-drug conjugate (ADC) is a targeted cancer therapy that combines an antibody with a biologically active drug or cytotoxin. This combination allows for the selective delivery of the drug to cancer cells, thereby minimizing the impact on healthy cells and reducing side effects.
Structure and Mechanism[edit | edit source]
An ADC consists of three main components:
- The antibody: A monoclonal antibody that specifically targets a tumor-associated antigen.
- The linker: A chemical bridge that connects the antibody to the drug. The linker is designed to be stable in the bloodstream but release the drug once inside the target cell.
- The cytotoxin: A potent drug that can kill cancer cells. Common cytotoxins used in ADCs include auristatins, maytansinoids, and calicheamicins.
The mechanism of action involves the binding of the ADC to the target antigen on the surface of the cancer cell. After binding, the ADC is internalized into the cell, where the linker is cleaved, releasing the cytotoxin to exert its cytotoxic effects.
Development and Approval[edit | edit source]
The development of ADCs involves several stages, including preclinical research, clinical trials, and regulatory approval. The first ADC to receive FDA approval was gemtuzumab ozogamicin in 2000 for the treatment of acute myeloid leukemia.
Clinical Applications[edit | edit source]
ADCs are primarily used in the treatment of various types of cancer, including:
Advantages and Challenges[edit | edit source]
Advantages[edit | edit source]
- Targeted delivery of cytotoxins to cancer cells
- Reduced systemic toxicity
- Potential for combination with other therapies
Challenges[edit | edit source]
- Development of resistance
- Complexity of manufacturing
- High cost of treatment
Future Directions[edit | edit source]
Research is ongoing to improve the efficacy and safety of ADCs. Innovations include the development of new linkers, more potent cytotoxins, and antibodies with higher specificity.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
